Stock Track | Revolution Medicines (RVMD) Surges 5.74% in Pre-market Following Analyst Buy Ratings

Stock Track

May 08, 2025

Shares of Revolution Medicines, Inc. (RVMD) soared 5.74% in pre-market trading on Thursday, as the biotech company received positive analyst coverage. The stock's upward movement comes on the heels of multiple "Buy" ratings from Wall Street analysts, highlighting the company's potential in the healthcare sector.

Two prominent analysts have reiterated their bullish stance on Revolution Medicines. Alec Stranahan maintained a "Buy" recommendation, emphasizing the promise of the company's RAS(ON) platform and its strong financial position. Similarly, Peter Lawson from Barclays reaffirmed a "Buy" rating on RVMD, demonstrating confidence in the company's prospects.

Despite the overall positive sentiment, Guggenheim adjusted its target price for Revolution Medicines, lowering it from $87 to $80. However, this adjustment does not appear to have dampened investor enthusiasm, as evidenced by the stock's significant pre-market gain. The continued "Buy" ratings from multiple analysts seem to be outweighing any concerns, suggesting that investors remain optimistic about Revolution Medicines' future in the competitive biotech landscape.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1143647286"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143647286\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143647286?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-08 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143647286","market":"us","top_or_hot":-1,"title":"Stock Track | Revolution Medicines (RVMD) Surges 5.74% in Pre-market Following Analyst Buy Ratings","media":"Stock Track","content":"<p>Shares of Revolution Medicines, Inc. (RVMD) soared 5.74% in pre-market trading on Thursday, as the biotech company received positive analyst coverage. The stock's upward movement comes on the heels of multiple \"Buy\" ratings from Wall Street analysts, highlighting the company's potential in the healthcare sector.</p>\n\n<p>Two prominent analysts have reiterated their bullish stance on Revolution Medicines. Alec Stranahan maintained a \"Buy\" recommendation, emphasizing the promise of the company's RAS(ON) platform and its strong financial position. Similarly, Peter Lawson from Barclays reaffirmed a \"Buy\" rating on RVMD, demonstrating confidence in the company's prospects.</p>\n\n<p>Despite the overall positive sentiment, Guggenheim adjusted its target price for Revolution Medicines, lowering it from $87 to $80. However, this adjustment does not appear to have dampened investor enthusiasm, as evidenced by the stock's significant pre-market gain. The continued \"Buy\" ratings from multiple analysts seem to be outweighing any concerns, suggesting that investors remain optimistic about Revolution Medicines' future in the competitive biotech landscape.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Revolution Medicines (RVMD) Surges 5.74% in Pre-market Following Analyst Buy Ratings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Revolution Medicines (RVMD) Surges 5.74% in Pre-market Following Analyst Buy Ratings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-08 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Revolution Medicines, Inc. (RVMD) soared 5.74% in pre-market trading on Thursday, as the biotech company received positive analyst coverage. The stock's upward movement comes on the heels of multiple \"Buy\" ratings from Wall Street analysts, highlighting the company's potential in the healthcare sector.</p>\n\n<p>Two prominent analysts have reiterated their bullish stance on Revolution Medicines. Alec Stranahan maintained a \"Buy\" recommendation, emphasizing the promise of the company's RAS(ON) platform and its strong financial position. Similarly, Peter Lawson from Barclays reaffirmed a \"Buy\" rating on RVMD, demonstrating confidence in the company's prospects.</p>\n\n<p>Despite the overall positive sentiment, Guggenheim adjusted its target price for Revolution Medicines, lowering it from $87 to $80. However, this adjustment does not appear to have dampened investor enthusiasm, as evidenced by the stock's significant pre-market gain. The continued \"Buy\" ratings from multiple analysts seem to be outweighing any concerns, suggesting that investors remain optimistic about Revolution Medicines' future in the competitive biotech landscape.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"","article_id":"1143647286","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143647286","pubTimestamp":1746705657,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Revolution Medicines, Inc.  soared 5.74% in pre-market trading on Thursday, as the biotech company received positive analyst coverage. The stock's upward movement comes on the heels of multiple \"Buy\" ratings from Wall Street analysts, highlighting the company's potential in the healthcare sector.Two prominent analysts have reiterated their bullish stance on Revolution Medicines. Alec Stranahan maintained a \"Buy\" recommendation, emphasizing the promise of the company's RAS platform and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc."},"translate_title":"股票赛道Revolution Medicines(RVMD)在分析师给予买入评级后盘前飙升5.74%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1},"content_text":"Shares of Revolution Medicines, Inc. (RVMD) soared 5.74% in pre-market trading on Thursday, as the biotech company received positive analyst coverage. The stock's upward movement comes on the heels of multiple \"Buy\" ratings from Wall Street analysts, highlighting the company's potential in the healthcare sector.\nTwo prominent analysts have reiterated their bullish stance on Revolution Medicines. Alec Stranahan maintained a \"Buy\" recommendation, emphasizing the promise of the company's RAS(ON) platform and its strong financial position. Similarly, Peter Lawson from Barclays reaffirmed a \"Buy\" rating on RVMD, demonstrating confidence in the company's prospects.\nDespite the overall positive sentiment, Guggenheim adjusted its target price for Revolution Medicines, lowering it from $87 to $80. However, this adjustment does not appear to have dampened investor enthusiasm, as evidenced by the stock's significant pre-market gain. The continued \"Buy\" ratings from multiple analysts seem to be outweighing any concerns, suggesting that investors remain optimistic about Revolution Medicines' future in the competitive biotech landscape.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}